GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Other Cash Payments from Operating Activities

BioXcel Therapeutics (FRA:BX2) Other Cash Payments from Operating Activities


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Other Cash Payments from Operating Activities?

Other Cash Payments from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


BioXcel Therapeutics (FRA:BX2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Other Cash Payments from Operating Activities
Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.